Sickle Cell Disease Patients

View All

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment
Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

History has been created as the world captures the significance of the FDA’s approval of Casgevy (exa-cel), a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease (SCD). This groundbreaking therapy represents a long-awaited potential cure for the debilitatin...

Find More

Sickle cell disease treatment
Novel treatment approval promises a better future for Sickle cell disease patients

Sickle cell disease is a haematological, genetic disorder that affects millions of people worldwide. According to the NIH, “Sickle cell disease is the most common inherited blood disorder in the United States, affecting 70,000 to 80,000 Americans’’. The estimates are somewhat similar to that of CDC’s according t...

Find More